Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
(2023) Promising bioactive metabolites of mangrove inhabitant Streptomyces tauricus and prostate cancer PC3 cell inhibition by antimicrobial peptides
Two cohorts from the general population (Rotterdam and France) were included in the validation set
Conclusion: Clinical outcomes in patients treated with nivolumab and regorafenib after sorafenib failure did not differ significantly
(PubMed) Ferrante KL, Shefner J, Zhang H, et al
2017;169(1):132-147.e16
US$ 27.70
US$ 28.01
US$ 20.15
US$ 22.44
US$ 25.31
